The regulatory approvals of nusinersen and tofersen, plus the large body of clinical and preclinical data from other drugs, have significantly de-risked antisense technology for neurological diseases. The platform learnings over the last 2 decades can be applied to subsequent drugs to improve the efficiency of discovering effective neuro-therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neuron.2023.05.027 | DOI Listing |
Publication Analysis
Top Keywords
neurological diseases
8
antisense drugs
4
drugs rare
4
rare ultra-rare
4
ultra-rare genetic
4
genetic neurological
4
diseases regulatory
4
regulatory approvals
4
approvals nusinersen
4
nusinersen tofersen
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!